Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000947871-25-000636
Filing Date
2025-07-01
Accepted
2025-07-01 21:23:37
Documents
1
Period of Report
2025-06-27

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 10664
  Complete submission text file 0000947871-25-000636.txt   12887
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 4 | Act: 34 | File No.: 001-37719 | Film No.: 251098147

Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 212-739-6400
OrbiMed Capital GP V LLC (Reporting) CIK: 0001615374 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-37719 | Film No.: 251098146

Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Issuer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)